Vaccination News Home Page

http://ipsapp003.lwwonline.com/content/getfile/1980/98/12/abstract.htm

What was the rate prior to widespread use of vaccines such as Hib? For more on this, click here. - SM

Previous Abstract  | Full Text  | Full Text PDF (86 K)  | References (9)  | Next Abstract

 

The Pediatric Infectious Disease Journal 2002; 21(10):947-950

Population-based epidemiology of invasive pneumococcal infection in children in nine urban centers in Canada, 1994 through 1998

GORDEAN L. BJORNSON, MBA; DAVID W. SCHEIFELE, MD; SCOTT A. HALPERIN, MD; AND MEMBERS OF THE CANADIAN PAEDIATRIC SOCIETY/HEALTH CANADA IMMUNIZATION MONITORING PROGRAM, ACTIVE (IMPACT)

Purpose.

To describe the epidemiology of invasive pneumococcal infections in Canadian children 0 to 12 years old.

Methods.

At each of nine urban centers, active surveillance was conducted to identify all cases of invasive pneumococcal infection in children during 1994 to 1998. Postal codes were used to distinguish cases resident in defined urban areas from referral cases. Census data were obtained for each defined area to calculate age-specific incidence rates. Features of population-based cases were described.

Results.

From an average defined population of ~1 million children, 937 eligible cases arose. Those 6 to 17 months old had the highest average incidence rate of 98.6/100 000/year. The average cumulative risk of infection was 1 in 460 between birth and 59 months, by which age 92% of cases had occurred. Among cases younger than 2 years of age, simple bacteremia accounted for 66%, pneumonia with bacteremia accounted for 14.7% and meningitis accounted for 11% (average incidence rate, 9.0/100 000/year). An underlying illness was present in 16% of all cases. The mortality rate was 1.8%.

Conclusions.

Invasive pneumococcal infections are relatively common in early childhood, based on 5 years of data from nearly 20% of the Canadian population ages 0 to 12 years. These data will be valuable for calculating the economic case for universal infant vaccination with newly available vaccines.
Key words: Streptococcus pneumoniae; invasive infection; population-based incidence rates; children

From the Vaccine Evaluation Center, University of British Columbia, Vancouver, British Columbia (GLB, DWS); Clinical Trials Research Center, Dalhousie University, Halifax, Nova Scotia (SAH); and IMPACT, Ottawa, Canada.

Accepted for publication May 28, 2002.

The Pediatric Infectious Disease Journal 2002; 21(10):947-950
Copyright © 2002 Lippincott Williams & Wilkins
All rights reserved

 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.